Asthma Cell Models for Research

Asthma is a chronic inflammatory disease of the airways affecting over 260 million people globally, with approximately 455,000 deaths annually (WHO, 2023). The prevalence has been increasing, particularly in children and in urbanized regions. Asthma imposes a significant economic burden due to healthcare costs and lost productivity. While mortality rates have declined in many countries, severe asthma remains a major cause of morbidity. The disease is heterogeneous, with phenotypes such as allergic, non-allergic, late-onset, and obesity-related asthma, each with distinct pathophysiological mechanisms. The 5-year survival is not typically used for asthma, but severe exacerbations can be life-threatening. Key risk factors include genetic predisposition, early-life infections, allergen exposure, air pollution, and obesity. Asthma is a major focus for drug development due to its high prevalence and the need for better therapies, especially for severe, corticosteroid-resistant forms.

Asthma is an ideal disease for mechanistic studies because of its well-characterized immune and structural cell involvement. The airway epithelium, smooth muscle cells, and immune cells such as Th2 lymphocytes, eosinophils, and mast cells play critical roles. Public datasets, such as the Gene Expression Omnibus (GEO) and the Asthma Biobank, provide extensive transcriptomic and epigenomic data. Open questions include the molecular basis of asthma heterogeneity, the role of epithelial barrier dysfunction, and the mechanisms of corticosteroid resistance. Gene-edited cell models are essential for dissecting these pathways and validating therapeutic targets.

Asthma is not a cancer, but it involves inflammatory signaling pathways. The key pathways include:

• • Th2/Type 2 inflammation: IL-4, IL-5, IL-13 signaling via JAK-STAT pathway.
• • Epithelial barrier dysfunction: Defects in tight junctions and increased expression of alarmins (TSLP, IL-33, IL-25).
• • Airway remodeling: TGF-β signaling leading to fibrosis and smooth muscle hypertrophy.
• • Oxidative stress: Nrf2 pathway and reactive oxygen species (ROS) production.

These pathways are interconnected and contribute to airway hyperresponsiveness and chronic inflammation.

Asthma is a complex genetic disease, but certain genes have been consistently associated. The following table lists key genes with their alteration frequencies and functional effects, based on GWAS and targeted sequencing studies (from NCBI, ClinVar, and literature).

These variants are not necessarily somatic mutations but genetic risk factors.

Asthma involves several deregulated signaling networks:

• • JAK-STAT pathway: Activated by IL-4 and IL-13, leading to STAT6 phosphorylation and Th2 gene expression.
• • NF-κB pathway: Mediates pro-inflammatory cytokine production in response to allergens and oxidative stress.
• • MAPK pathway: ERK and p38 are involved in smooth muscle contraction and cytokine production.
• • PI3K/AKT pathway: Promotes cell survival and proliferation in airway smooth muscle and epithelial cells.
• • TGF-β pathway: Drives airway remodeling and fibrosis.

Key nodes include:

• • IL-4Rα, IL-13Rα1, STAT6, GATA3, TSLP, IL-33, ST2, NF-κB, p38, ERK, PI3K, TGF-βR.

Commonly used cell lines for asthma research include:

Organoids derived from airway epithelial cells (bronchial organoids) are increasingly used to model asthma because they recapitulate 3D architecture and cell-cell interactions. They can be generated from patient-derived cells and used for drug testing.

Animal models for asthma include:

• • Allergen-induced models: Mice sensitized with ovalbumin (OVA) or house dust mite (HDM) extract to induce Th2 inflammation.
• • Genetically engineered mouse models (GEMM): Knockout or transgenic mice for key genes (e.g., IL-13, IL-4, STAT6) to study their roles.
• • Humanized mice: Mice engrafted with human immune cells to study human-specific responses.
• • Patient-derived xenografts (PDX): Not commonly used for asthma, but lung tissue from asthmatics can be transplanted into immunodeficient mice for limited studies.

These models have limitations, such as species differences and lack of chronicity, but remain valuable for mechanistic studies.

Gene-edited cell models are powerful tools for asthma research. CRISPR-Cas9 technology allows the creation of isogenic cell lines with specific gene knockouts or knock-ins. For example:

• • IL-13 knockout A549 cells: To study the role of IL-13 in epithelial inflammation.
• • IL-4Rα knockout BEAS-2B cells: To investigate IL-4/IL-13 signaling.
• • TSLP knock-in reporter cell lines: To monitor TSLP expression.
• • ORMDL3 knockout 16HBE14o- cells: To study sphingolipid metabolism and airway hyperresponsiveness.

These models are sequence-verified and commercially available from various sources, ensuring reproducibility. They are essential for target validation and drug screening. Isogenic pairs (wild-type vs. knockout) allow precise assessment of gene function without confounding genetic background.

Gene-edited cells are used to validate the function of asthma-associated genes. For example, knocking out ORMDL3 in bronchial epithelial cells can reveal its role in sphingolipid metabolism and airway inflammation. Similarly, IL-13 knockout in A549 cells can confirm its contribution to mucus hypersecretion. These models help prioritize therapeutic targets.

Isogenic cell lines are used for high-throughput screening of anti-inflammatory compounds. For instance, a reporter cell line with a fluorescent tag under the control of an IL-13-responsive promoter can be used to screen for inhibitors of IL-13 signaling. Additionally, gene-edited cells can model corticosteroid resistance by knocking out genes involved in glucocorticoid receptor signaling, such as GR or MKP-1, to identify alternative therapies.

CRISPR screens can identify genes whose knockout sensitizes cells to certain treatments or alters cytokine production. For example, a genome-wide CRISPR knockout screen in airway epithelial cells can identify genes that regulate TSLP expression, providing potential biomarkers or drug targets. Synthetic lethality screens can also be performed to find vulnerabilities in asthma-associated pathways.